By The Sunday Times –
Professor Sir Magdi Yacoub has pioneered a new technique for which patients will thank him with all their hearts.
We live in an age of medical wonders. Even so, the latest breakthrough from a team led by Sir Magdi Yacoub stands out.
The surgeon, who pioneered techniques to transplant organs into the human body, has now come up with a way for the body to grow vital replacement parts for itself.
His team is inserting temporary valves made of microscopic fibres into the hearts of patients. Living cells colonise the fibres — which then dissolve, leaving a healthy valve made of the patient’s own tissue.
The term “medical miracle” has become meaningless with overuse, but here it is surely justified. There is a whiff of the magical about the process.
Such innovations are often greeted as revolutionary one day and taken for grantedthe next.
Still, we suspect those lucky enough to benefit from the treatment will never lose sight of its wonder. For years to come, they will have reason to thank Professor Yacoub and his team — with all their hearts.
***
The ‘holy grail’ of heart health: a valve that grows inside you
Even the surgeon behind Britain’s first heart-lung transplant thinks this will eclipse his other achievements: artificial scaffolding that means no one will need repeat surgery
BARRY LEWIS / ALAMY
Heart valves that grow inside the body are to be tested in British cardiac patients in a breakthrough for regenerative medicine.
More than 50 initial patients will receive a temporary valve made of microscopic fibres. It acts as a scaffold which, once implanted, infuses with the body’s cells. The scaffold then dissolves over the following months, leaving a self-grown living valve made of the patient’s own tissue.
Cardiologists said it would be especially useful for young children with congenital heart defects because the new valve will grow with them. At present artificial valves have to be replaced every few years.
The development is being spearheaded by Professor Sir Magdi Yacoub, a pioneering cardiac surgeon who performed Britain’s first heart-lung transplant at Harefield Hospital in northwest London. He has operated on more than 20,000 patients in a 50-year career.
Now in his eighties and still working at the same hospital, he believes this could be his most important contribution to medicine.
“Throughout the years I have been working, I have witnessed an epidemic of valve disease which kills so many people,” he said. “I have been trying all my life to take experience from the lab to the clinic. This I consider one of the most important things I want to leave behind as a legacy — the biggest present to mankind.”
ROS DRINKWATER FOR THE TIMES
ROS DRINKWATER FOR THE TIMES
Scientists have been attempting for years to develop valve replacements engineered from the body’s own tissue.
Today patients who need valve replacement surgery are fitted with either artificial valves, meaning they have to take anti-clotting medication for life, or biological ones made of pig, cow or donated human tissue, which typically last ten to 15 years. Both can be rejected by the body.
About 13,000 heart valve replacement surgeries are performed in England each year and 300,000 worldwide, a number set to rise as heart disease rates climb. By 2050, 850,000 replacements a year are expected globally.
Heart valve problems affect an estimated one in four over-60s, caused by ageing, inflammation and infection. Congenital defects also cause valve conditions, affecting an estimated eight in 1,000 babies born in the UK.
When valves are diseased, they become stiff and narrowed or leaky and ineffective, meaning they either do not open fully or close properly when controlling blood flow around the heart. Left untreated, this can result in heart failure, stroke or a heart attack.
Children born with congenital heart valve disease typically need at least five procedures to replace valves before adulthood because artificial valves do not grow with them. Every operation carries a risk of complications, including infection, excessive bleeding, stroke, blood clots and kidney problems.
GEOFF PUGH/SHUTTERSTOCK
The living valve could be life-changing for patients because it would eliminate the need for repeat surgeries and the risk of rejection.
Yacoub said: “I always say nature is the greatest technology. It is so superior to anything we can make. Once something is living — whether that’s a cell, tissue or [the living valve] — it adapts on its own. Biology is like magic.”
To make the valve, scientists spray a cobweb of very fine fibres into a 3D replica of a human heart valve, creating a scaffold. This is held together by a knitted mesh “jacket” of fibres which can withstand the pressure of pulsating blood flow. The tiny fibres are made of polycaprolactone, a biodegradable polymer commonly used as a coating for tablets, which slowly breaks down in the body into harmless carbon dioxide and water.
To mimic nature, the fibres are of different widths and have specific spaces between them which attract cells; this creates an environment where they thrive. After settling into these spaces, cells grow and trigger the development of the different cell types needed to make the heart valve work.
A study of the device in sheep, published a year ago in the journal Nature Communications Biology, revealed that within four weeks there were more than 20 different types of cell — including nerve and fatty tissue cells — functioning in the exact places they would be in a natural heart valve.
Although other researchers around the world have tried to create living valves, this project, run by the company Heart Biotech at Harefield Hospital, is the first to have successfully stimulated the growth of nerve cells. Within six months of implantation, the structure is made up of living cells from the patient’s body, and within a year or two it will have dissolved, leaving the patient with a new heart valve grown from their own cells. It will continue to grow with them throughout their lives.
Researchers have received funding from the British and German governments. The first human trials, expected to start in 18 months, will include 50 to 100 patients, including adults with expired heart valve replacements and children who would otherwise face multiple risky operations in a short time.
The trials will test how the device performs compared with an established artificial valve and will be carried out by an international team including doctors based at University College London and Great Ormond Street hospitals, as well as participants in New York, Italy and the Netherlands.
In the first trials, the living valve will be used to replace the pulmonary valve, which controls blood flow to the lungs, as this is under the least pressure. But scientists are confident it will soon be ready for all types of valve replacement.
Dr Sonya Babu-Narayan, associate medical director of the British Heart Foundation, described a tissue-engineered heart valve replacement as “the holy grail” for the surgical treatment for heart valve disease.
She said: “It is early days, but if further research shows the approach is successful in humans, many people around the world could live well for longer without the need for repeated heart valve procedures.”
___________________
